Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003078 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix
A Phase 3 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 870
- Enrollment target
- 20
- Study locations
NCT00003078: Completed Phase 3 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.
NCT00003078 is a Phase 3 study of Cervical Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 870 participants, above the 564-participant average among 144 other Cervical Cancer trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003078, a Phase 3 study of Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 870 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy and chemotherapy may kill more tumor cells. It is not known whether receiving radiation therapy plus cisplatin is more effective than receiving radiation therapy plus fluorouracil in treating patients with cancer of the cervix. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus cisplatin or fluorouracil in treating patients with primary stage IIB, stage IIIB, or stage IVA cancer of the cervix.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG fluorouracil
- RADIATION radiation therapy
- RADIATION brachytherapy
Study Locations (20)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Chao Family Comprehensive Cancer Center - Orange
- Women's Cancer Center - Palo Alto
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
- CCOP - Central Illinois - Decatur
- CCOP - Evanston - Evanston
District of Columbia
- Vincent T. Lombardi Cancer Research Center, Georgetown University - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Florida
- Fred J. Woods Radiation Therapy Center/St. Joseph's Cancer Institute - Tampa
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Alabama
- University of Alabama Comprehensive Cancer Center - Birmingham
Arizona
- CCOP - Greater Phoenix - Phoenix
Colorado
- University of Colorado Cancer Center - Denver
Georgia
- Emory University Hospital - Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 870 participants |
| Start Date | 1997-10 |
| Phase | Phase 3 |
What the finished NCT00003078 record still lists
NCT00003078 is an interventional study that assigns participants to a tested intervention. The registered 870 participants enrollment target is mid-sized for trials with a published cap, above the 564-participant average among 144 other Cervical Cancer trials with a reported enrollment target (54% higher).
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00003078 names 20 study sites across 12 states, led by California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00003078 about?
NCT00003078 is a clinical study titled "Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy and chemotherapy may kill more tumor cells. It is not known whether receiving radiation...
What is the current status of trial NCT00003078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 870 participants. The study started on 1997-10.
What conditions does trial NCT00003078 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT00003078?
The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), radiation therapy (RADIATION), brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT00003078?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003078 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003078's enrollment target sits among peer trials
870 17th of 144 higher than 128 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
RECRUITING · Phase 3
-
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
COMPLETED · Phase 3
-
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
COMPLETED · Phase 3
-
Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer
COMPLETED · Phase 3
-
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia